Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H16F3N3O3 |
| Molecular Weight | 403.3545 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1[C@H](N)CN1C2=CC3=C(C=C2F)C(=O)C(=CN3C4=C(F)C=C(F)C=C4)C(O)=O
InChI
InChIKey=LTDOHCZUKCZDEQ-BJOHPYRUSA-N
InChI=1S/C20H16F3N3O3/c1-9-15(24)8-25(9)18-6-17-11(5-14(18)23)19(27)12(20(28)29)7-26(17)16-3-2-10(21)4-13(16)22/h2-7,9,15H,8,24H2,1H3,(H,28,29)/t9-,15+/m0/s1
| Molecular Formula | C20H16F3N3O3 |
| Molecular Weight | 403.3545 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cetefloxacin is an oral fluoroquinolone derivative with potent antibacterial activity against a broad spectrum of microorganisms being particularly active against gram-positive bacteria. Cetefloxacin is highly toxic and mortality was recorded among rats receiving 2000 or 1000 mg/kg/d. Rats receiving dosages of 450 or 2000/1000 mg/kg/d showed less activated mandibular lymph nodes, cortical lymphocyte depletion of mandibular and/or mesenteric lymph nodes, atrophy of the white pulp of the spleen, cortical atrophy of thymus and thymic apoptosis. Enlarged caeca, increased water consumption and variations in plasma electrolyte levels were observed in animals receiving these dosages and in male rats receiving 100 mg/kg/d. Low neutrophil counts were observed in rats receiving dosages of 100 or 450 mg/kg/d, and increased alkaline phosphatase and alanine transaminase plasma levels and slightly decreased plasma protein levels in females receiving 450 or 2000/1000 mg/kg/d. Marmosets receiving dosages of 50 mg/kg/d and above displayed several clinical signs which included emesis, diarrhoea, ptosis, occasional episodes of under- and overactivity, and excessive scratching activity. Skin reddening was observed during the first week of treatment in marmosets receiving 300 mg/kg/d.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11413745
rats: 100, 450, 2000 mg/kg/d
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:28:47 GMT 2025
by
admin
on
Wed Apr 02 08:28:47 GMT 2025
|
| Record UNII |
CFY01MZD5T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30161810
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
7041
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
CFY01MZD5T
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
C76230
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
141725-88-4
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
CHEMBL132468
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
100000081491
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
SUB07447MIG
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY | |||
|
65995
Created by
admin on Wed Apr 02 08:28:47 GMT 2025 , Edited by admin on Wed Apr 02 08:28:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |